Ligand Pharmaceuticals: Dominance in the Biopharma Royalty Market – Licensing Revenues Expected to Increase by 23% Annually by 2030!

Ligand Pharmaceuticals stands out in the biopharmaceutical industry with a high-margin, low-risk licensing model in a Royalty market worth over 29 billion USD. Key products like Filspari and Ohtuvayre, along with the newly raised forecast for 2026, are expected to boost licensing revenues by an average of 23% per year until 2030. With 1 billion USD in available capital, further investments in new drug candidates can secure growth for the coming decades. Ligand Pharmaceuticals (LGND) operates as a highly profitable biopharma royalty holding...